These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 31345074)

  • 61. Bioresorbable vascular scaffold in patients with complex coronary artery disease.
    Tamburino CI; Capranzano P; Longo G; Immè S; Tamburino G; Scalia M; Condorelli A; Francaviglia B; LA Manna A; Sgroi C; Grasso C; DI Salvo ME; Capodanno D; Tamburino C
    Minerva Cardioangiol; 2016 Aug; 64(4):481-6. PubMed ID: 27128353
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
    Serruys PW; Onuma Y; Ormiston JA; de Bruyne B; Regar E; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Miquel-Hebert K; Rapoza R; García-García HM
    Circulation; 2010 Nov; 122(22):2301-12. PubMed ID: 21098436
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trial.
    Arroyo D; Gendre G; Schukraft S; Kallinikou Z; Müller O; Baeriswyl G; Stauffer JC; Goy JJ; Togni M; Cook S; Puricel S
    Int J Cardiol; 2017 Sep; 243():121-125. PubMed ID: 28576627
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Safety and performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial.
    Haude M; Erbel R; Erne P; Verheye S; Degen H; Vermeersch P; Weissman N; Prati F; Bruining N; Waksman R; Koolen J
    EuroIntervention; 2016 Jun; 12(2):e160-6. PubMed ID: 27290675
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Role of invasive imaging in acute and long-term assessment of bioresorbable scaffold technology.
    Chamié D; Garcia-Garcia H; Costa RA; Onuma Y; Abizaid A; Serruys PW
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):38-53. PubMed ID: 27797463
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Current and future perspectives on drug-eluting bioresorbable coronary scaffolds.
    Ielasi A; Tespili M
    Future Cardiol; 2014 May; 10(3):409-20. PubMed ID: 24976477
    [TBL] [Abstract][Full Text] [Related]  

  • 67. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy.
    Ali ZA; Serruys PW; Kimura T; Gao R; Ellis SG; Kereiakes DJ; Onuma Y; Simonton C; Zhang Z; Stone GW
    Lancet; 2017 Aug; 390(10096):760-772. PubMed ID: 28732815
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Bioresorbable Stents: Is This Where We Are Headed?
    Wayangankar SA; Ellis SG
    Prog Cardiovasc Dis; 2015; 58(3):342-55. PubMed ID: 26319497
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
    Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
    Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Imaging and functional assessment of bioresorbable scaffolds.
    Pighi M; Tanguay JF; L'allier PL
    Minerva Cardioangiol; 2016 Aug; 64(4):442-61. PubMed ID: 27195663
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Coronary artery perforation at the level of two-overlapping bioresorbable vascular scaffolds: The importance of vessel sizing and scaffold thickness.
    Pichette M; Chevalier F; Généreux P
    Catheter Cardiovasc Interv; 2015 Oct; 86(4):686-91. PubMed ID: 26122768
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Bioresorbable scaffold - A magic bullet for the treatment of coronary artery disease?
    Brie D; Penson P; Serban MC; Toth PP; Simonton C; Serruys PW; Banach M
    Int J Cardiol; 2016 Jul; 215():47-59. PubMed ID: 27111160
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: from bench to clinical use.
    Sotomi Y; Suwannasom P; Tenekecioglu E; Tateishi H; Abdelghani M; Serruys PW; Onuma Y
    Expert Rev Cardiovasc Ther; 2015 Oct; 13(10):1127-45. PubMed ID: 26401921
    [TBL] [Abstract][Full Text] [Related]  

  • 75. In vivo serial invasive imaging of the second-generation drug-eluting absorbable metal scaffold (Magmaris - DREAMS 2G) in de novo coronary lesions: Insights from the BIOSOLVE-II First-In-Man Trial.
    Garcia-Garcia HM; Haude M; Kuku K; Hideo-Kajita A; Ince H; Abizaid A; Tölg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Escaned J; Dijkstra J; Waksman R
    Int J Cardiol; 2018 Mar; 255():22-28. PubMed ID: 29292064
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions.
    Abizaid A; Costa RA; Schofer J; Ormiston J; Maeng M; Witzenbichler B; Botelho RV; Costa JR; Chamié D; Abizaid AS; Castro JP; Morrison L; Toyloy S; Bhat V; Yan J; Verheye S
    JACC Cardiovasc Interv; 2016 Mar; 9(6):565-74. PubMed ID: 27013155
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Outcomes of the two generations of bioresorbable scaffolds (Magmaris vs. Absorb) in acute coronary syndrome in routine clinical practice.
    Rola P; Włodarczak A; Łanocha M; Barycki M; Szudrowicz M; Kulczycki JJ; Jaroszewska-Pozorska J; Gosiewska A; Woźnica K; Lesiak M; Doroszko A
    Cardiol J; 2022 May; 30(6):870-80. PubMed ID: 35621089
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German-Austrian ABSORB RegIstRy (GABI-R).
    Nef H; Wiebe J; Achenbach S; Münzel T; Naber C; Richardt G; Mehilli J; Wöhrle J; Neumann T; Biermann J; Zahn R; Kastner J; Schmermund A; Pfannebecker T; Schneider S; Limbourg T; Hamm CW
    Cardiovasc Revasc Med; 2016; 17(1):34-7. PubMed ID: 26431767
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial.
    Gao R; Yang Y; Han Y; Huo Y; Chen J; Yu B; Su X; Li L; Kuo HC; Ying SW; Cheong WF; Zhang Y; Su X; Xu B; Popma JJ; Stone GW;
    J Am Coll Cardiol; 2015 Dec; 66(21):2298-2309. PubMed ID: 26471805
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Serial observation of drug-eluting absorbable metal scaffold: multi-imaging modality assessment.
    Waksman R; Prati F; Bruining N; Haude M; Böse D; Kitabata H; Erne P; Verheye S; Degen H; Vermeersch P; Di Vito L; Koolen J; Erbel R
    Circ Cardiovasc Interv; 2013 Dec; 6(6):644-53. PubMed ID: 24254708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.